Evidence map›Paper›PMID 37197407›Full record

ArticleFrontiers in pharmacology2023

Stimulatory effects of

Khalid Alghamdi, Zeyad Alehaideb, Ashok Kumar, Hamad Al-Eidi, Sahar S Alghamdi, Rasha Suliman, Rizwan Ali, Feras Almourfi, Saleh M Alghamdi, Mohamed Boudjelal and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Khalid AlghamdiDepartment of Dermatology (DOD), College of Medicine (COM), King Saud University (KSU), Riyadh, Saudi Arabia.
Zeyad AlehaidebDepartment of Core Medical Research Facility and Platform, King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
Ashok KumarDepartment of Dermatology (DOD), College of Medicine (COM), King Saud University (KSU), Riyadh, Saudi Arabia.
Hamad Al-EidiCell and Gene Therapy Group, Medical Genomics Research Department, KAIMRC, KSAU-HS, MNGHA, Riyadh, Saudi Arabia.
Sahar S AlghamdiDepartment of Core Medical Research Facility and Platform, King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
Rasha SulimanDepartment of Pharmacy, Fatima College of Health Sciences, Abu Dhabi, United Arab Emirates.
Rizwan AliDepartment of Core Medical Research Facility and Platform, King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
Feras AlmourfiDepartment of Core Medical Research Facility and Platform, King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
Saleh M AlghamdiResearch Centre, King Fahad Medical City, Riyadh, Saudi Arabia.
Mohamed BoudjelalDepartment of Core Medical Research Facility and Platform, King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
Sabine Matou-NasriCell and Gene Therapy Group, Medical Genomics Research Department, KAIMRC, KSAU-HS, MNGHA, Riyadh, Saudi Arabia.
King Saud bin Abdulaziz University for Health Sciences · SAKing Saud University · SAKing Abdullah International Medical Research Center · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is no first-line treatment for vitiligo, a skin disease characterized by a lack of melanin produced by the melanocytes, resulting in an urgent demand for new therapeutic drugs capable of stimulating melanocyte functions, including melanogenesis. In this study, traditional medicinal plant extracts were tested for cultured human melanocyte proliferation, migration, and melanogenesis using MTT, scratch wound-healing assays, transmission electron microscopy, immunofluorescence staining, and Western blot technology. Of the methanolic extracts,

Indexed as

human melanocyteLycium shawiimelaninmelanogenesisnatural productskin depigmentationvitiligo

Identifiers

PMID37197407
PMCPMC10184183
OpenAlexW4366828071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.